Uttar Pradesh News Desk

Hereditary Angioedema Market, Size, Trends, Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Hereditary Angioedema Market, Size, Trends, Epidemiology Forecast till 2030

September 03
16:18 2020
Hereditary Angioedema Market, Size, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Hereditary Angioedema , historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) resulting in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx.

 

Hereditary Angioedema Market Insight

Hereditary Angioedema Market Size in 7MM in 2017 was USD 1,741.75 million

Hereditary Angioedema Market Drivers

  • Rising Prevalence
  • Introduction of Oral Therapy
  • Increase in R&D

Hereditary Angioedema Market Barriers

  • Misdiagnosis and under-diagnosis
  • High treatment Cost

 

Hereditary Angioedema market overall has been segmented into two treatment strategies that are commonly used for HAE as on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible and further as long-term prophylaxis of attacks. Short-term (or periprocedural) prophylaxis treatment is taken before activities that are known to trigger attacks. 

Over recent years, significant advances have been made about HAE management, and the potential is greater than ever before for affected patients to move closer to living a life that is not overshadowed by disease morbidity. A range of effective therapies have become available, and treatment can now be managed at home by most patients, even with injectable agents. A growing understanding of the underlying pathophysiology of HAE has facilitated the development of several targeted therapies, and ongoing progress in this area will likely continue to improve prophylactic options for HAE as well as refine the disease, particularly in recently identified subtypes with normal C1 inhibitor. Additional laboratory and clinical research may identify biomarkers useful in predicting clinical phenotypes and/or response to various therapeutic agents.

The landscape of therapeutic options for Hereditary Angioedema patients has changed dramatically in the last two decades. Ongoing research promises even greater change in the foreseeable future. Given the economic and psychosocial burdens for patients living with angioedema, effective therapies with novel mechanisms will offer more choices for patients and physicians, as well as provide greater flexibility in routes of administration.

 

Request for sample pages
Table of contents

1. Key Insights

2. Executive Summary of Hereditary Angioedema

3. Competitive Intelligence Analysis for Hereditary Angioedema

4. Hereditary Angioedema : Market Overview at a Glance

4.1. Hereditary Angioedema Total Market Share (%) Distribution in 2017

4.2. Hereditary Angioedema Total Market Share (%) Distribution in 2030

5. Hereditary Angioedema : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Hereditary Angioedema Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Hereditary Angioedema Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Hereditary Angioedema Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Hereditary Angioedema Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Hereditary Angioedema Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Hereditary Angioedema Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Hereditary Angioedema Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Hereditary Angioedema Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Hereditary Angioedema Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Hereditary Angioedema Treatment and Management

8.2. Hereditary Angioedema Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Hereditary Angioedema Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Hereditary Angioedema : Seven Major Market Analysis

13.1. Key Findings

13.2. Hereditary Angioedema Market Size in 7MM

13.3. Hereditary Angioedema Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Hereditary Angioedema Total Market Size in the United States

15.1.2. Hereditary Angioedema Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Hereditary Angioedema Total Market Size in Germany

15.3.2. Hereditary Angioedema Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Hereditary Angioedema Total Market Size in France

15.4.2. Hereditary Angioedema Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Hereditary Angioedema Total Market Size in Italy

15.5.2. Hereditary Angioedema Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Hereditary Angioedema Total Market Size in Spain

15.6.2. Hereditary Angioedema Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Hereditary Angioedema Total Market Size in the United Kingdom

15.7.2. Hereditary Angioedema Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Hereditary Angioedema Total Market Size in Japan

15.8.3. Hereditary Angioedema Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Hereditary Angioedema

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles